Clinical trial
Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma…
NCT00306566 · Cytos Biotechnology AG, Industry · Completed
Key facts
| NCT number | NCT00306566 |
|---|---|
| Title | Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients |
| Official title | A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage II Malignant Melanoma |
| Lead sponsor | Cytos Biotechnology AG, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Biological |
| Interventions | CYT004-MelQbG10 |
| First posted | Mar 24, 2006 |
| Last update posted | Sep 20, 2007 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: